EUVIMEDEUVIMED entdecken
Leitlinie

Practice Guideline for Methylphenidate Use in Persons With Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine

David B Arciniegas, Ronald T Seel, Stephen N Macciocchi, David X Cifu, Yelena Goldin Frazier, Darryl L Kaelin, Douglas I Katz, Tolu O Oyesanya, Amy K Wagner

Archives of Physical Medicine and Rehabilitation · 2026-04 · 107 (4) · 753-760

DOI: 10.1016/j.apmr.2025.08.024 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Archives of Physical Medicine and Rehabilitation, 2026-04. Verfasst von David B Arciniegas und 8 weiteren Autor:innen. Beteiligte Einrichtung: Behavioral Neurology Section, Department of Neurology, University of Colorado School of Medicine, Aurora, CO; Department of Psychiatry and Behavioral…. Hauptthemen laut MEDLINE: Methylphenidate, Brain Injuries, Traumatic, Central Nervous System Stimulants, Physical and Rehabilitation Medicine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Cancer Aid and Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This clinical practice guideline (CPG) provides evidence-informed recommendations on the use of methylphenidate hydrochloride (MPH) in adults with cognitive and noncognitive neuropsychiatric symptoms in the subacute or chronic periods after traumatic brain injury (TBI). The CPG was developed by an American Congress of Rehabilitation Medicine multidisciplinary author panel with expertise in brain injury rehabilitation and included professionals in physical medicine and rehabilitation, basic/translational science, neurology, behavioral neurology and neuropsychiatry, nursing, and neuropsychology. Rationales and recommendations were written based on evidence from an accompanying systematic review. The generation and finalization of CPG recommendations followed procedures in the 2017 American Academy of Neurology Guideline Development and Process Manual. Clinicians should establish a therapeutic alliance and apply principles of pharmacotherapy in persons with TBI to identify indications for and contraindications to MPH use, facilitate treatment adherence, and optimize outcomes. MPH should be offered to improve sustained attention and processing speed performance and may be offered to improve selective attention performance among adults with TBI. MPH should be offered to improve depressive symptoms among adult patients with TBI in whom rapid resolution of depressive symptoms and/or treatment of co-occurring cognitive impairments are clinical priorities. MPH should not be offered to improve performance in executive functioning or working memory among adults with TBI. Although MPH is usually well tolerated among adults with TBI, clinicians should follow standard assessment, education, dosing, and monitoring recommendations when prescribing MPH to optimize its safety and tolerability. A summary of all recommendations on the use of MPH in TBI is available at the end of the CPG.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethylphenidateBrain Injuries, TraumaticCentral Nervous System StimulantsPhysical and Rehabilitation MedicineHumansUnited StatesAdult

Stichwörter der Autor:innen

AttentionCognitionDepressionMeta-analysisMethylphenidatePractice guidelineRehabilitationSystematic reviewTraumatic brain injury

Substanzen

MethylphenidateCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Behavioral Neurology Section, Department of Neurology, University of Colorado School of Medicine, Aurora, CO; Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, N…
  • Center for Rehabilitation Science and Engineering, Department of Physical Medicine & Rehabilitation, Virginia Commonwealth University School of Medicine, Richmond, VA. Electronic address: ronald.seel@vcuhealth.org.
  • Atlanta Neuropsychology, LLC, Atlanta, GA.
  • Center for Rehabilitation Science and Engineering, Department of Physical Medicine & Rehabilitation, Virginia Commonwealth University School of Medicine, Richmond, VA.
  • JFK Johnson Rehabilitation Institute, Edison, NJ; Department of Physical Medicine and Rehabilitation, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ.
  • Division of Physical Medicine and Rehabilitation; Department of Neurological Surgery, University of Louisville School of Medicine, Louisville, KY.

Förderung

  • Cancer Aid and Research Fund

Zitieren

APA

Arciniegas, D. B., Seel, R. T., Macciocchi, S. N., Cifu, D. X., Frazier, Y. G., Kaelin, D. L., Katz, D. I., Oyesanya, T. O., & Wagner, A. K. (2026). Practice Guideline for Methylphenidate Use in Persons With Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine. Archives of Physical Medicine and Rehabilitation, 107(4), 753-760. https://doi.org/10.1016/j.apmr.2025.08.024

Vancouver

Arciniegas DB, Seel RT, Macciocchi SN, Cifu DX, Frazier YG, Kaelin DL, et al. Practice Guideline for Methylphenidate Use in Persons With Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine. Archives of Physical Medicine and Rehabilitation. 2026;107(4):753-760. doi:10.1016/j.apmr.2025.08.024

BibTeX
@article{Arciniegas2026,
  author = {Arciniegas, David B and Seel, Ronald T and Macciocchi, Stephen N and Cifu, David X and Frazier, Yelena Goldin and Kaelin, Darryl L and Katz, Douglas I and Oyesanya, Tolu O and Wagner, Amy K},
  title = {Practice Guideline for Methylphenidate Use in Persons With Traumatic Brain Injury: Report of the American Congress of Rehabilitation Medicine},
  journal = {Archives of Physical Medicine and Rehabilitation},
  year = {2026},
  volume = {107},
  number = {4},
  pages = {753--760},
  doi = {10.1016/j.apmr.2025.08.024}
}
Kostenlos starten →